



## Financial Tear Sheet

### Corporate Profile

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. Schering-Plough is a publicly traded company with shares listed on the New York Stock Exchange (ticker symbol SGP).


### Stock Performance

#### SGP (Common Stock)

Exchange	NYSE (US Dollar)
Price	\$36.46
Change (%)	▲ 1.13 (3.20%)
Volume	36,364,804
52 Week Low	\$20.05
Market Cap	\$0
Rolling EPS	3.80
PE Ratio	9.5947

#### Shares Outstanding

Data as of 11/20/09 4:00 p.m. ET



### Recent Headlines & Events

November 03, 2009 - 12:00 a.m.

**Merck and Schering-Plough to Complete Merger Today**

November 02, 2009 - 5:31 p.m.

**Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C**

November 02, 2009 - 10:27 a.m.

**Schering-Plough Announces Sponsorship of Rabies-Control Projects in India**

There are currently no events scheduled.

### SEC Filings

Filing Date	Form	
Nov. 18, 2009	<b>8-K/A</b>	
Nov. 18, 2009	<b>15-12B</b>	
Nov. 16, 2009	<b>4</b>	
Nov. 09, 2009	<b>EFFECT</b>	

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed